Richard Riedel, MD
Internal Medicine · Durham, NCNPI 1235227844
Payments from drug & device makers
Across 548 payments — averaging $4666.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1.3M
- Deciphera Pharmaceuticals Inc.$304K
- Servier Bioinnovation$270K
- Blueprint Medicines Corporation$229K
- Karyopharm Therapeutics Inc.$80K
- Daiichi Sankyo Inc.$69K
- plus $271K from 16 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 160 | $1,335,024 |
| Deciphera Pharmaceuticals Inc. | 170 | $303,643 |
| Servier Bioinnovation | 15 | $269,799 |
| Blueprint Medicines Corporation | 18 | $229,044 |
| Karyopharm Therapeutics Inc. | 32 | $80,415 |
| Daiichi Sankyo Inc. | 63 | $68,679 |
| Springworks Therapeutics, Inc. | 24 | $46,911 |
| Adaptimmune LLC | 4 | $42,166 |
| Epizyme, Inc. | 3 | $38,244 |
| Genentech, Inc. | 8 | $36,439 |
| PTC Therapeutics, Inc. | 1 | $29,187 |
| Trillium Therapeutics USA, LLC | 9 | $28,022 |
| Boehringer Ingelheim | 12 | $12,224 |
| Aadi Bioscience, Inc. | 12 | $7,883 |
| Recordati_rare_diseases_inc. | 7 | $7,111 |
| Ipsen Biopharmaceuticals, Inc | 1 | $5,460 |
| Pfizer | 3 | $5,147 |
| EMD Serono, Inc. | 1 | $4,275 |
| EMD Serono Research & Development Institute, Inc. | 1 | $3,800 |
| Bayer | 2 | $3,600 |
| Galvanize Therapeutics, Inc | 1 | $178 |
| AstraZeneca | 1 | $68 |
How this compares
$2,557,318 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Durham
- Manesh PatelDurham$27.2M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- April SalamaDurham$6.5M
- Hope UronisDurham$5M
- Jamie ToddDurham$1.9M
- Nirmish ShahDurham$1.8M
- Aparna SwaminathanDurham$1.2M
- Cynthia MoylanDurham$907K
- Mehri McKellarDurham$824K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.